Achilles Therapeutics Reports Third Quarter 2024 Financial Results
ACHL
globenewswire.comNovember 14, 2024
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
Achilles Therapeutics to Present at Upcoming Conferences
ACHL
GlobeNewsWireJune 12, 2023
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:
3 Stocks With 1,000% Upside Potential
ACHL
InvestorPlaceMay 21, 2023
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.